Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study.
Clin Genitourin Cancer. 2020 Feb 08;:
Urol Oncol. 2020 Feb 11;:
Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to Assess the Value of Abiraterone and Enzalutamide in Advanced Prostate Cancer.
JCO Oncol Pract. 2020 Feb;16(2):e201-e210
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
J Clin Oncol. 2020 Feb 07;:JCO1902044
Eur J Cancer. 2020 Mar;127:158-159
Curr Oncol Rep. 2020 Feb 01;22(2):14
Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer.
Can Urol Assoc J. 2020 Feb;14(2):17-23
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs.
Cancer. 2020 Apr 01;126(7):1550-1558
Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials.
Ann Oncol. 2020 Jan;31(1):50-60
Balancing efficacy and financial toxicity in the management of metastatic castration-sensitive prostate cancer.
Can Urol Assoc J. 2019 Dec;13(12):404-405